SCHEMBL2351981

SCHEMBL2351981

CCOC(=O)CCc1cc(F)c(OCc2cccc(OCC)c2)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.46
PPARA Q07869 1/20 0.46
FFAR1 O14842 13/20 0.46
THRA P10827 3/20 0.46
THRB P10828 3/20 0.46
PPARD Q03181 3/20 0.45
MAOB P27338 1/20 0.43
FFAR4 Q5NUL3 4/20 0.43
TP53 P04637 1/20 0.43
PKM P14618 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MRGPRX4 Q96LA9 1/20 0.43
ESR1 P03372 1/20 0.42
NR3C1 P04150 1/20 0.42
PGR P06401 1/20 0.42
NR3C2 P08235 1/20 0.42
AR P10275 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2350395 0.92 FFAR1 (0.50) FFAR1THRATHRBMAOBMRGPRX4
SCHEMBL2349696 0.91 FFAR1 (0.47) PPARGPPARAFFAR1THRATHRB
SCHEMBL2349318 0.91 FFAR1 (0.43) PPARGPPARAFFAR1THRATHRB
SCHEMBL2350368 0.90 FFAR1 (0.56) FFAR1THRATHRBFFAR4
SCHEMBL12394599 0.90 FFAR1 (0.43) PPARGPPARAFFAR1THRATHRB
SCHEMBL2352418 0.90 FFAR1 (0.58) FFAR1THRATHRBPPARDFFAR4
SCHEMBL2347031 0.88 THRA (0.47) FFAR1THRATHRBMAOBFFAR4
SCHEMBL2354294 0.88 FFAR1 (0.61) PPARGPPARAFFAR1THRATHRB
SCHEMBL2350121 0.88 FFAR1 (0.53) PPARGPPARAFFAR1THRATHRB
SCHEMBL2350355 0.87 FFAR1 (0.52) FFAR1THRATHRBFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1688138-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2006-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167378-A1 Receptor Function Regulation Agent GPR119, INSR, GPR88 PPARG 210/4885PPARA 283/4885FFAR1 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.